In the post-COVID-19 era, people suffer from depression, anxiety and other psychological problems. Depressive disorder remains the mental disorder with the highest global disease burden. At present, the drug therapy effect of Depressive disorder is still not ideal. Some symptom dimensions of depressive disorder patients are still difficult in current treatment, and adverse drug reactions have also become an important reason why depressive disorder patients cannot adhere to long-term drug therapy. How to improve drug efficacy and prognosis of depressive disorder?
Depression disorder is a complex disease involving 5-HT, NE and DA monoaminergic transmitter disorders. Disturbances in these three transmitter systems can lead to different depressive symptoms by affecting different brain regions. Depression disorder is caused by the decreased activity of 5-HT, NE and DA transmitters. A new antidepressant, Torudivenlafaxine hydrochloride sustained-release tablets, can simultaneously inhibit the reuptake of three transmitters, 5-HT, NE and DA. In theory, the synergistic intervention of 5-HT, NE and DA can improve the efficacy of antidepressant and the improvement of adverse drug reactions.

Liangmei Chen, female, chief physician. Graduated from West China Medical University in June 1999; From September 2008 to June 2011, she received a master’s degree in clinical psychology from the Fourth Military Medical University. Good at diagnosis and treatment of psychiatric diseases and psychological counseling, especially for schizophrenia, depression, geriatric disorders and other diseases have accumulated rich clinical experience. She has won the excellent paper award for many times and Xi’an 17th Natural Science Excellent Academic Paper third prize in 2018. Written a series of popular science books on mental health: Confused Old Man and Seeking Medical Treatment for Mental and Psychological Diseases; Translated and published Abnormal Psychology, a classic textbook of American original psychology. She is Xi’an city science and technology project evaluation expert database member, and Xi’an Health and Family Planning Commission senior title evaluation committee evaluation expert.